Table 6.
Summary of adverse reactions in each treatment group
| Adverse reactions | Curcumina (N = 70) |
Diclofenacb (N = 69) |
RR | RRLB | RRUB | NNT |
|---|---|---|---|---|---|---|
| n (%) | n (%) | |||||
| Total number of patients experiencing AEs* | 9 (13%) | 26 (38%) | ||||
| Dyspepsia | 0 | 6 (8.7%) | 0.08** | 0 | 1.3 | 12 |
| Nausea | 6 (9%) | 7 (10.14%) | 0.8 | 0.3 | 2.4 | 64 |
| Vomiting | 0 | 7 (10.14%) | 0.07** | 0 | 1.1 | 10 |
| Diarrhea | 5 (7%) | 8 (11.6%) | 0.6 | 0.2 | 1.8 | 23 |
| Constipation | 0 | 6 (8.7%) | 0.08** | 0 | 1.3 | 12 |
| Abdominal pain/acidity | 0 | 19 (27.53%) | 0.03** | 0 | 0.4*** | 4 |
| Flatulence | 0 | 9 (13.04%) | 0.05** | 0 | 0.9*** | 8 |
| Upper respiratory tract infection | 0 | 5 (7.25%) | 0.09** | 0 | 1.6 | 14 |
Values are expressed as absolute number of patients (percentage) in each category
Abbreviations: a treatment group, b control group, n number of patients in each category, N total number of patients in each treatment group, NNT number needed to treat, RR relative risk, RRLB relative risk lower boundary, RRUB relative risk upper boundary
*P <0.01 for curcumin versus diclofenac
**Clinically significant adverse event (AE) (RR <0.5)
***Statistically significant AE (95% confidence interval does not include 1)